Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief